India Activists Claim U.S. Steps Up Lobbying Against Compulsory License
This article was originally published in PharmAsia News
Executive Summary
Foreign drug makers complaining about India's use of its compulsory licensing law to allow a generic of a Bayer patent-protected cancer drug appear to have the active backing of the U.S. government.